Search Results

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Braintale to Showcase Data on Exploratory Sub-study of Minoryx’s Pivotal ADVANCE Phase 2/3 Study at 33 rd ENRS Conference

Braintale, a medtech that is deciphering white matter, spin off from the Assistance Publique-Hôpitaux de Paris, showcases, with Minoryx, a biotechnology company developing a treatment for X-linked Adrenoleukodystrophy, the results of the multicentric ADVANCE sub study with Braintale biomarker platform on the occasion of the American Academy of Neurology.

Following disappointing results for an antibiotic candidate whose development program is now being suspended, Spero Therapeutics is looking to extend its cash runway while it focuses on other assets in its pipeline.

Following two layoffs in less than three months, Viracta Therapeutics may have around 18 employees left to advance its efforts to bring lead product candidate nana-val to market.

Minoryx will receive an upfront and milestone payments of up to $78 million, as well as double digit royalties on annual net sales

Relay Therapeutics is cutting its workforce to help streamline its research organization as it looks to complete its first large-scale, pivotal clinical trial.

Minoryx Therapeutics opens Belgian subsidiary that will lead important development activities